Residual postoperative paralysis. Pancuronium versus mivacurium, does it matter?

A F Kopman1, J Ng, L M Zank

  • 1New York Medical College, Valhalla, USA. akopman@aol.com

Anesthesiology
|December 1, 1996
PubMed
Abstract

Insights

Postoperative residual paralysis is common, but using tactile train-of-four (TOF) monitoring can reduce its incidence. Short-acting neuromuscular blockers offer a wider margin of safety for full recovery.

Area of Science:

  • Anesthesiology
  • Pharmacology
  • Critical Care Medicine

Background:

  • Postoperative residual paralysis (POP) is a frequent complication in postanesthesia care units (PACUs).
  • Existing studies often lack detailed anesthetic management information.
  • Comparative studies on long- and short-acting neuromuscular blockers are scarce.

Purpose of the Study:

  • To reexamine the incidence of postoperative weakness after administering long- and short-acting neuromuscular blockers.
  • To compare the recovery profiles of mivacurium and pancuronium.
  • To evaluate the effectiveness of tactile train-of-four (TOF) monitoring in guiding neuromuscular blockade reversal.

Main Methods:

  • Ninety-one adult patients were divided into three groups receiving mivacurium or pancuronium.
  • Anesthesia was induced and maintained using various agents including propofol, fentanyl, desflurane, and nitrous oxide.
  • Neuromuscular blockade was monitored using tactile TOF stimulation, with reversal agents administered based on twitch response.

Main Results:

  • All patients receiving mivacurium achieved TOF ratios greater than 0.80 in the PACU, with many reaching 0.90 in the operating room.
  • Patients receiving pancuronium showed slower recovery, with some not reaching a TOF ratio of 0.90 within 90 minutes of reversal.
  • Recovery parameters did not differ between pancuronium-desflurane and pancuronium-propofol anesthesia groups.

Conclusions:

  • Tactile TOF monitoring can minimize postoperative weakness in the PACU, even with long-acting neuromuscular blockers.
  • Full recovery (TOF ratio ≥ 0.90) is more consistently achieved with short-acting agents like mivacurium.
  • Nondepolarizing neuromuscular blockers require careful monitoring for safe patient recovery.

Related Concept Videos

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics01:11

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
Depolarizing Blockers: Mechanism of Action01:28

Depolarizing Blockers: Mechanism of Action

Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...